r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction

Laura A. Sullivan, Juliet G. Carbon, Christina L. Roland et al. · 2010

Read r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction by Laura A. Sullivan, Juliet G. Carbon, Christina L. Roland et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0012031.txt.

Description

Laura Sullivan and co-workers introduced in 2010 a new antibody designed to starve tumors of their blood supply signal. VEGF is critical for vessel growth in health and disease, and inside tumors it keeps vessel cells alive, leaks fluid, and calls in new growth. Most anti-VEGF drugs of the era bound only the human form, limiting animal testing.

The antibody, r84, binds both mouse and human VEGF, showed potent anti-tumor activity, and induced limited toxicity. Cross-species binding lets researchers test the same drug in mice and then people without switching molecules. Strong tumor control with modest side effects is exactly the profile angiogenesis therapy keeps chasing.

Catalog record

CREATORLaura A. Sullivan, Juliet G. Carbon, Christina L. Roland et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012031

Browse the full library · About the Tower of Babel